They will come to inspect after the horse has bolted from the stable,” grumbles a visibly miffed Kiran Mazumdar-Shaw. The chairman and managing director of Biocon is seated in her tastefully decorated meeting room at the Bengaluru headquarters, where the walls are adorned with paintings by Scottish artist Tom Robertson and bright sunlight pours in through the large windows. The Watson & Creek meeting room is named after the Nobel laureates who discovered DNA; in fact, all meeting rooms at India’s largest biotech firm are named after Nobel Prize winning scientists. This is just another sign that Biocon takes its research seriously, the biggest indicator, of course, being that like most other large Indian pharmas, it is working at breakneck speed to be the first to launch an Indian blockbuster drug. And that explains why Mazumdar-Shaw is unhappy.
Lead Story
Critical condition
Drug majors are shifting clinical trials out of India as lawmakers turn on the heat
Kiran Mazumdar-Shaw|Biocon|Merck Sharp & Dohme|GSK|Swasthya Adhikar Manch|Drugs and Cosmetics Act|Swati Piramal|Piramal Enterprises|Ranjit Roy Chaudhury|Roy Chaudhary committee|New Drug Advisory Committees|Jamila Joseph|Reliance Life Sciences|Ranjit Shahani|Novartis India|Shoibal Mukherjee|Quintiles|Dr Reddy’s Laboratories|Sun Pharma|KV Subramaniam|Suneela Thatte|Saurendra Das|Excel Life Sciences
Editor's Pick
Most Popular
Summer wine and salad
Kishore Singh - January 19, 2015
A double topping for growth
Meghna Maiti - January 15, 2015
Scriptures for success
Kripa Mahalingam - January 27, 2015
Where's the party tonight?
Aditi Saxena - January 27, 2015
The million-dollar question: Is investing a game of luck or skill?
Shankar Sharma - May 04, 2021